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ABSTRACT
Objective: To identify factors predicting early death in
women with breast cancer.
Design: Cohort study.
Setting: 29 trusts across seven cancer networks in the
North Thames area.
Participants: 15037 women with primary breast
cancer diagnosed between January 1996 and
December 2005.
Methods: Logistic regression analyses to determine
predictors of early death and factors associated with
lack of surgical treatment.
Main exposures: Age at diagnosis, mode of
presentation, ethnicity, disease severity, comorbidities,
treatment and period of diagnosis in relation to the
Cancer Plan (the NHS’s strategy in 2000 for
investment in and reform of cancer services).
Main outcome measures: Death from any cause
within 1 year of diagnosis, and receipt of surgical
treatment.
Results: By 31 December 2006, 4765 women had
died, 980 in the year after diagnosis. Older age and
disease severity independently predicted early death.
Women over 80 were more likely to die early than
women under 50 (OR 8.05, 95% CI 5.96 to 10.88).
Presence of distant metastases on diagnosis increased
the odds of early death more than eightfold (OR 8.41,
95% CI 6.49 to 10.89). Two or more recorded
comorbidities were associated with a nearly fourfold
increase. There was a signiﬁcant decrease in odds
associated with surgery (OR 0.29, 95% CI 0.24 to
0.35). Independently of disease severity and
comorbidities, women over 70 were less likely than
those under 50 to be treated surgically and this was
even more pronounced in those aged over 80 (OR
0.09, 95% CI 0.07 to 0.10). Other factors
independently associated with a reduced likelihood of
surgery included a non-screening presentation, non-
white ethnicity and additional comorbidities.
Conclusions: These ﬁndings may partially explain the
survival discrepancies between the UK and other
European countries in female patients with breast
cancer. The study identiﬁes a group of women with
a particularly poor prognosis for whom interventions
aiming at early detection may be targeted.
INTRODUCTION
Despite the decline in breast cancer mortality
seen in the UK since the late 1980s, survival
rates are still substantially lower than in many
other European countries.
1 2 It has been
difﬁcult to pinpoint the reasons for these
differences. One important observation in
some studies remains unexplained, namely
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ARTICLE SUMMARY
Article focus
- Several studies have shown that the UK has
lower survival for breast cancer than some other
European countries with a similar expenditure on
healthcare.
- Differences have been shown to occur mainly in
older patients and in the ﬁrst year after
diagnosis.
- Several reasons/explanations have been
proposed.
Key messages
- This study shows that patients with breast cancer
dying in the ﬁrst year after diagnosis are more
likely to be older and have more advanced
disease and existing comorbidities.
- Surgical treatment and (to a lesser extent)
radiotherapy and tamoxifen usage were associ-
ated with a reduced risk of early death.
- The likelihood of receiving surgery was inversely
related to age, independently of comorbidity and
disease severity.
- These ﬁndings suggest that early detection,
management of comorbidities and optimisation
of treatment of older patients are important
target areas to improve outcomes.
Strengths and limitations of this study
- This is a large cohort of women with a diagnosis
of breast cancer, and the results may be
generalisable to women treated for breast
cancer in the UK during the same time period.
- Many variables that may be related to both risk
factors and outcomes have not been assessed in
this study. However, their correlation with death
within a year would have to be very strong to
explain the strong associations seen in our data.
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Open Access Researchthat of poorer survival in UK patients soon after their
diagnosis. Sant et al
3 demonstrated a higher risk of death
in women with breast cancer in the UK in the ﬁrst
6 months after diagnosis than in other European coun-
tries. This was particularly pronounced for the youngest
(under 29 years) and oldest (over 80 years) age groups.
Six months from diagnosis, survival patterns in the UK
became more similar to those in the other European
countries. Further analysis of the survival differential has
revealed that disparities between the UK and northern
European countries (Sweden and Norway) occur mainly
for older women in the ﬁrst year after diagnosis.
4 Eighty-
one per cent of the excess UK deaths occur within
2 years of diagnosis.
Beral and Peto
5 have suggested that observed differ-
ences in survival may be due to bias relating to artefacts
in cancer registration rather than to genuine differences
in diagnosis and management of breast cancer. However,
a recent study by Møller et al
6 has shown that such effects
are unlikely to make a signiﬁcant contribution to
observed differences in survival. The effects of incom-
plete ascertainment and registration from death certiﬁ-
cates only on survival comparisons based on cancer
registry data have been investigated in detail by
Robinson et al.
7
The aim of this study was to investigate factors associ-
ated with early mortality (within 1 year after diagnosis)
in a sample of UK women given a diagnosis of breast
cancer during 1996e2005. Since surgical intervention
with a curative intent is strongly related to reduced
mortality, a secondary aim of the study was to identify the
patient characteristics most often associated with the
failure to use this treatment option.
SUBJECTS AND METHODS
We conducted a cohort study using data from the North
Thames Prospective Audit of Breast Cancer, set up in
1996 by Health Authorities in the North Thames area to
monitor the implementation of the CalmaneHine
recommendations in 29 trusts in seven participating
cancer networks: North London, North East London,
West London, South West London (Royal Marsden
Hospital, Brompton Road), Mount Vernon, Mid-Anglia
and South Essex. The audit used a common dataset and
a standard proforma across the providers to collect
detailed demographic, diagnostic and treatment data for
all new primary cases of malignant female breast cancer
diagnosed between January 1996 and December 2005.
Trained data collectors used either Thames Cancer
Registry (TCR) Access-based software or the British
Association of Surgical Oncology software for breast
audit to record information. The number of partici-
pating trusts varied from year to year, with a maximum
of 26 trusts submitting partial or complete datasets in
2000 and a minimum of seven trusts submitting data in
2005.
Women were followed from their date of entry into the
audit to death or censoring at 31 December 2006, an
average of 5.6 years. Date of death was conﬁrmed
through linking patients to the NHS Central Register
using the NHS Strategic Tracing Service or matching
with records in the TCR. For those who were neither
traced nor matched, date of death was taken from the
breast audit database, if it was recorded. Women who
were either traced or matched but who had no date of
death in any of the three databases were assumed to be
alive at 31 December 2006. Women who could not be
traced in the NHS Central Register or matched to
the TCR database and who had no date of death
recorded in the audit database were excluded from
analyses, as we could not be sure of their vital status. The
study also excluded women with in situ breast cancer
without any invasive component at diagnosis. After these
exclusions, a total of 15037 women were available for
analysis.
Data on different treatment modes (surgery, radio-
therapy, chemotherapy and tamoxifen) were taken from
the audit database, augmented by information from the
TCR database where possible. Cases were matched to
Hospital Episode Statistics (HES) data using name, NHS
number, date of birth and date of diagnosis within
90 days of that recorded in the audit database in order to
obtain further information on receipt of surgery.
Women with a C50 diagnosis (breast cancer) and a B or
T8 code in the HES surgery ﬁeld were regarded as
having had surgery. Only 98 cases were recoded on this
basis, illustrating the completeness of the audit database
in this respect.
Cause of death was available from the TCR database
for 85% of the women who died during the study period.
A categorical variable accounting for the calendar period
of diagnosis was included to adjust for diagnosis and
treatment in relation to the implementation of the
Cancer Plan (the NHS’s strategy in 2000 for investment
in and reform of cancer services). As per the method-
ology of Rachet et al,
8 the following periods were
considered: before 27 September 2000 (when the plan
was published); 28 September 2000 to 31 December
2003 (initialisation period); after 01 January 2004
(implementation). Patient age was categorised as:
<50 years, 50e59 years, 60e69 years, 70e79 years and
80 years and over. Pathological tumour size was assigned
to one of ﬁve groups: <10 mm, 10e19 mm, 20e39 mm,
40e49 mm and 50 mm and over. Information on addi-
tional diagnoses was obtained from the matched HES
dataset and was used to determine the Charlson
Comorbidity Index for matched patients. This is
a weighted index based on the number and severity of 17
potential serious comorbid conditions that affect
mortality.
9 The index was categorised into the groups 0,
1 and 2+.
Clinical, demographic, pathological and treatment-
related factors were compared between women who died
from any cause within 1 year of their diagnosis and those
who survived beyond this year. All-cause mortality, rather
than death from breast cancer, was used partly because
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women, but also because the international study
4 that
highlighted the adverse survival in English women in the
ﬁrst year after diagnosis was also based on all-cause
mortality. An analysis restricted to breast cancer-speciﬁc
mortality produced broadly similar results.
Univariate analyses were performed using c
2 tests and
unadjusted (bivariate) logistic regression models. A
multivariate logistic regression model investigated the
independent contribution of all covariates. This model
included surgery but not collinear covariatesdthat is,
variables that were only known for patients who had
surgery, namely tumour size and node status.
The regression models assessed the effects of age,
ethnicity, mode of presentation (screening, symptoms or
incidental), distant metastases at diagnosis, comorbid-
ities, period of diagnosis and treatments (surgery,
radiotherapy, tamoxifen and chemotherapy) on early
death from any cause. The results are presented as ORs,
both unadjusted (univariate) and fully adjusted (multi-
variate), with 95% CIs.
Additional logistic regression models were used to
determine which factors were associated with use of
surgery. All analyses were conducted using Stata V.10.
RESULTS
The study population consisted of 15037 women, of
whom 4456 (30%) were over 70 years old at the time of
their diagnosis. The majority of women (78%) presented
symptomatically, and 82% of those with known ethnicity
were recorded as white. Over a mean follow-up of
5.6 years, there were 4765 deaths. Table 1 shows the
underlying cause of death in these women. A total of 980
women (6.5% of the total cohort and 20.6% of all
deaths) died within a year of their diagnosis, and, of
these, 464 women were known to have died from breast
cancer. Among those for whom the cause of death was
known, there was no signiﬁcant difference in the
proportions dying from different causes between those
who died within or after the ﬁrst year since diagnosis
(c
2¼10.6; 9 df; p¼0.30). However, signiﬁcantly more of
the women who died early had an unrecorded cause of
death (26% vs 12%).
Table 2 describes the characteristics of women who
survived 1 year beyond diagnosis and those who did not,
and table 3 shows the results of the logistic regression
analyses. In univariate analyses (c
2 values in table 2 and
unadjusted ORs in table 3), older age (>60 years), white
ethnicity, distant metastases at diagnosis, positive nodes
and larger tumours (>20 mm) were all signiﬁcantly
linked with death within 1 year of diagnosis (p<0.001 for
all c
2 tests). Comorbidities on diagnosis were also asso-
ciated with an increased likelihood of early death
(Charlson Index $2: OR 5.55, 95% CI 4.56 to 6.76).
Women presenting because of symptoms (OR 7.91, 95%
CI 5.21 to 12.01) or whose cancer was discovered inci-
dentally (OR 11.98, 95% CI 7.37 to 19.48) were signiﬁ-
cantly more likely to die early, compared with those
whose cancer was identiﬁed through screening. ‘Inci-
dental’ cancers comprised non-symptomatic referrals
from any source other than routine screening or the
patient’s general practitioner.
Surgical treatment was associated with highly signiﬁ-
cantly reduced odds of early death from any cause (OR
0.12, 95% CI 0.11 to 0.14), as was treatment with
chemotherapy (OR 0.60, 95% CI 0.51 to 0.71) and
radiotherapy (OR 0.27, 95% CI 0.23 to 0.32). There was
no signiﬁcant association between tamoxifen usage and
early death (OR 0.94, 95% CI 0.79 to 1.12). The time
period in which women were diagnosed (before, during
or after implementation of the Cancer Plan) was not
signiﬁcantly associated with death within a year of diag-
nosis in univariate models (c
2¼3.54; p¼0.17).
The results of the multivariate logistic regression
analysis to assess the factors independently associated
with early death are shown as the adjusted ORs in
table 3. This model excluded tumour size and nodal
status, which are only known in women who received
Table 1 Cause of death in women with breast cancer by length of survival
Cause of death
Survival
Total <1 year from diagnosis >1 year from diagnosis
Number (%) Number (%) Number (%)
Breast cancer 464 (63.9) 2015 (60.5) 2479 (61.1)
Lung cancer 4 (0.6) 38 (1.1) 42 (1.0)
Colorectal cancer 3 (0.4) 32 (1.0) 35 (0.9)
Other/unspeciﬁed cancer 39 (5.4) 232 (7.0) 271 (6.7)
Ischaemic heart disease 34 (4.7) 137 (4.1) 171 (4.2)
Stroke 14 (1.9) 79 (2.4) 93 (2.3)
Other cardiovascular disease 43 (5.9) 204 (6.1) 247 (6.1)
Senility 16 (2.2) 92 (2.8) 108 (2.7)
Pneumonia 38 (5.2) 205 (6.2) 243 (6.0)
All other causes 71 (9.8) 294 (8.8) 365 (9.0)
Total with known cause of death 726 (100.0) 3328 (100.0) 4054 (100.0)
Cause of death not known 254 (25.9) 457 (12.1) 711 (14.9)
Total cases 980 3785 4765
Stapelkamp C, Holmberg L, Tataru D, et al. BMJ Open 2011;1:e000247. doi:10.1136/bmjopen-2011-000247 3
Predictors of early death in UK female breast cancer patientsTable 2 Characteristics of participants who did or did not survive the ﬁrst year after diagnosis
Patient characteristic
Survival
p Value*
<1 year from diagnosis >1 year from diagnosis
Number (%) Number (%)
Age at diagnosis (years)
<50 88 (9.0) 3712 (26.4) <0.001
50e59 91 (9.3) 3648 (26.0)
60e69 148 (15.1) 2894 (20.6)
70e79 270 (27.6) 2373 (16.9)
$80 383 (39.1) 1430 (10.2)
Ethnicity
Non-white 75 (7.7) 1983 (14.1) <0.001
White 488 (49.8) 8610 (61.3)
Not known 417 (42.6) 3464 (24.6)
Distant metastases at diagnosis
No 312 (31.8) 7977 (56.7) <0.001
Yes 156 (15.9) 271 (1.9)
Not known 512 (52.2) 5809 (41.3)
Tumour size (mm)
<10 12 (1.2) 1220 (8.7) <0.001
10e19 73 (7.4) 4016 (28.6)
20e39 83 (8.5) 3103 (22.1)
40e49 86 (8.8) 1953 (13.9)
$50 99 (10.1) 799 (5.7)
Not known 627 (64.0) 2966 (21.1)
Node status
Negative 95 (9.7) 5492 (39.1) <0.001
Positive 167 (17.0) 4213 (30.0)
Not known 718 (73.3) 4352 (31.0)
Charlson Index (comorbidities)
0 (minor) 203 (20.7) 6755 (48.1) <0.001
1 (moderate) 48 (4.9) 359 (2.6)
$2 (severe) 231 (23.6) 1384 (9.8)
Not known 498 (50.8) 5559 (39.5)
Diagnosis date (in relation to Cancer Plan)
Pre 2000 624 (63.7) 9057 (64.4) 0.79
2000e2003 292 (29.8) 3897 (27.7)
Post 2003 64 (6.5) 1103 (7.8)
Presentation
Screening 23 (2.3) 2274 (16.2) <0.001
Symptoms 763 (77.9) 9531 (67.8)
Incidental 64 (6.5) 528 (3.8)
Not known 130 (13.3) 1724 (12.3)
Surgery
No 489 (49.9) 1513 (10.8) <0.001
Yes 491 (50.1) 12544 (89.2)
Radiotherapy
No 454 (46.3) 3395 (24.2) <0.001
Yes 256 (26.1) 7079 (50.4)
Not known 270 (27.6) 3583 (25.5)
Chemotherapy
No 520 (53.1) 6482 (46.1) <0.001
Yes 203 (20.7) 4200 (29.9)
Not known 257 (26.2) 3375 (24.0)
Tamoxifen
No 172 (17.6) 2321 (16.5) 0.49
Yes 601 (61.3) 8630 (61.4)
Not known 207 (21.1) 3106 (22.1)
Total cases 980 14057
*p Value for comparison of proportions, excluding ‘not known’ category where present. For age, tumour size, Charlson Index and Cancer Plan,
test is for trend; for all other factors, test is for heterogeneity.
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Predictors of early death in UK female breast cancer patientsTable 3 Crude and adjusted ORs and 95% CIs for early death from any cause
Factor Number of cases
Early deaths,
number (%)
OR (95% CI)
Unadjusted Adjusted*
Age at diagnosis (years)
<50 3800 88 (2.3) 1.00 (e) 1.00 (e)
50e59 3739 91 (2.4) 1.05 (0.78 to 1.42) 1.41 (1.03 to 1.93)
60e69 3042 148 (4.9) 2.16 (1.65 to 2.82) 2.61 (1.94 to 3.50)
70e79 2643 270 (10.2) 4.80 (3.75 to 6.14) 4.62 (3.45 to 6.18)
$80 1813 383 (21.1) 11.30 (8.89 to 14.36) 8.05 (5.96 to 10.88)
Ethnicity
Non-white 2058 75 (3.6) 1.00 (e) 1.00 (e)
White 9098 488 (5.4) 1.50 (1.17 to 1.92) 1.25 (0.96 to 1.63)
Not known 3881 417 (10.7) 3.18 (2.47 to 4.09) 2.24 1.70 to 2.94)
Distant metastases at diagnosis
No 8289 312 (3.8) 1.00 (e) 1.00 (e)
Yes 427 156 (36.5) 14.72 (11.73 to 18.47) 8.41 (6.49 to 10.89)
Not known 6321 512 (8.1) 2.25 (1.95 to 2.60) 1.35 (1.13 to 1.60)
Tumour size (mm)
<10 1232 12 (1.0) 1.00 (e) e
10e19 4089 73 (1.8) 1.85 (1.00 to 3.41) e
20e39 3186 83 (2.6) 2.72 (1.48 to 5.00) e
40e49 2039 86 (4.2) 4.48 (2.44 to 8.22) e
$50 898 99 (11.0) 12.60 (6.87 to 23.08) e
Not known 3593 627 (17.4) 21.49 12.09 to 38.20) e
Node status
Negative 5587 95 (1.7) 1.00 (e) e
Positive 4380 167 (3.8) 2.29 (1.78 to 2.96) e
Not known 5070 718 (14.2) 9.54 (7.67 to 11.86) e
Charlson Index (comorbidities)
0 (minor) 6958 203 (2.9) 1.00 (e) 1.00 (e)
1 (moderate) 407 48 (11.8) 4.45 (3.19 to 6.20) 2.54 (1.77 to 3.65)
2+ (severe) 1615 231 (14.3) 5.55 (4.56 to 6.76) 3.55 (2.85 to 4.42)
Not known 6057 498 (8.2) 2.98 (2.52 to 3.52) 1.10 (0.90 to 1.34)
Diagnosis date (in relation to Cancer Plan)
Pre 2000 9681 624 (6.4) 1.00 (e) 1.00 (e)
2000e2003 4189 292 (7.0) 1.09 (0.94 to 1.26) 0.90 (0.75 to 1.07
Post 2003 1167 64 (5.5) 0.84 (0.65 to 1.10) 0.71 (0.52 to 0.98)
Presentation
Screening 2297 23 (1.0) 1.00 (e) 1.00 (e)
Symptoms 10294 763 (7.4) 7.91 (5.21 to 12.01) 3.31 (2.13 to 5.14)
Incidental 592 64 (10.8) 11.98 (7.37 to 19.48) 3.92 (2.30 to 6.66)
Not known 1854 130 (7.0) 7.46 (4.76 to 11.67) 2.77 (1.72 to 4.48)
Surgery
No 2002 489 (24.4) 1.00 (e) 1.00 (e)
Yes 13035 491 (3.8) 0.12 (0.11 to 0.14) 0.29 (0.24 to 0.35)
Radiotherapy
No 3849 454 (11.8) 1.00 (e) 1.00 (e)
Yes 7335 256 (3.5) 0.27 (0.23 to 0.32) 0.61 (0.51 to 0.74)
Not known 3853 270 (7.0) 0.56 (0.48 to 0.66) 0.65 (0.48 to 0.87)
Chemotherapy
No 7002 520 (7.4) 1.00 (e) 1.00 (e)
Yes 4403 203 (4.6) 0.60 (0.51 to 0.71) 1.49 (1.19 to 1.86)
Not known 3632 257 (7.1) 0.95 (0.81 to 1.11) 1.20 (0.89 to 1.62)
Tamoxifen
No 2493 172 (6.9) 1.00 (e) 1.00 (e)
Yes 9231 601 (6.5) 0.94 (0.79 to 1.12) 0.64 (0.51 to 0.80)
Not known 3313 207 (6.2) 0.90 (0.73 to 1.11) 0.93 (0.70 to 1.24)
*Adjusted for all other factorsdthat is, based on model that includes all factors.
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Predictors of early death in UK female breast cancer patientssurgical treatment. There was a clear and independent
association between increasing age and the risk of early
death, with an eightfold increase in the odds of early
death in women aged 80 or more compared with those
aged <50 at diagnosis (OR: 8.05, 95% CI 5.96 to 10.88).
In this adjusted analysis, white ethnicity was not inde-
pendently associated with early death. The signiﬁcant
associations noted in the univariate analyses were upheld
(although generally attenuated) in the multivariate
model, except for chemotherapy. Women receiving
chemotherapy were more likely than those not treated
with chemotherapy to die within a year of their diagnosis
(OR 1.49, 95% CI 1.19 to 1.86). Surgery was associated
with a reduced risk of early death (OR 0.29, 95% CI 0.24
to 0.35), as was radiotherapy (OR 0.61, 95% CI 0.51 to
0.74) and also tamoxifen (OR 0.64, 95% CI 0.51 to 0.80).
Women who were most recently diagnosed with
breast cancer (post-2003) were less likely to die early
(OR 0.71, 95% CI 0.52 to 0.98). Women with missing
data for ethnicity, presentation or metastases were at
increased risk of early death compared with the
reference categories.
Overall, 13.3% of women did not have surgery as part
of their treatment (table 2), and this proportion was
signiﬁcantly greater in women who died within a year of
diagnosis (50% vs 11%). The characteristics of women
who did or did not receive surgical treatment are shown
in table 4. Those receiving surgery were signiﬁcantly
younger, and were more likely to present via screening,
to be free of metastases at diagnosis, and to have fewer
comorbidities. For those of known ethnicity, there was
no difference in the proportions receiving surgery
between white and non-white women. However, the
proportion of cases with unknown ethnicity was signiﬁ-
cantly greater in those not receiving surgery (38.7% vs
23.8%).
In multivariate analysis (table 5), mode of presenta-
tion, older age (particularly $80 years), distant metas-
tases on presentation and comorbidities were
independent predictors of no surgical treatment
(70e79years old vs <50 years old: OR 0.27, 95% CI 0.23
to 0.33; $80 years old versus <50 years old: OR 0.09,
95% CI 0.07 to 0.10; symptomatic presentation versus
screening: OR 0.34, 95% CI 0.26 to 0.45; incidental
presentation versus screening: OR 0.28, 95% CI 0.20 to
0.40; distant metastases on diagnosis: OR 0.16, 95% CI
0.12 to 0.20; severe comorbidities: OR 0.50, 95% CI 0.41
to 0.62). White ethnicity was independently linked with
an increased likelihood of surgical treatment compared
with non-white ethnicity (OR 1.39, 95% CI 1.16 to 1.65).
DISCUSSION
Poorer prognosis of older women with breast cancer has
been attributed variously to treatment received,
10e17
more severe disease on presentation,
13 18e21 and the
presence of comorbidities.
10 Stage was identiﬁed as the
most important factor explaining breast cancer survival
discrepancies between European countries for women
given a diagnosis between 1990 and 1992,
19 particularly
in older age groups.
This study in more than 15000 women diagnosed as
having breast cancer in the North Thames area found
that age and disease severity at diagnosis were indepen-
dent predictors of early death from any cause. In the
women analysed here, distant metastases on diagnosis
were a strong predictor of early death, increasing the
odds of dying within a year of diagnosis more than
eightfold (OR 8.41, 95% CI 6.49 to 10.89). This effect
Table 4 Characteristics of women who did or did not have
surgery
Patient
characteristic
Surgery, number (%)
p Value* No Yes
Age at diagnosis (years)
<50 213 (10.6) 3587 (27.5) <0.001
50e59 182 (9.1) 3557 (27.3)
60e69 219 (10.9) 2823 (21.7)
70e79 526 (26.3) 2117 (16.2)
$80 862 (43.1) 951 (7.3)
Ethnicity
Non-white 238 (11.9) 1820 (14.0) 0.36y
White 989 (49.4) 8109 (62.2)
Not known 775 (38.7) 3106 (23.8)
Distant metastases at diagnosis
No 680 (34.0) 7609 (58.4) <0.001
Yes 151 (7.5) 276 (2.1)
Not known 1171 (58.5) 5150 (39.5)
Charlson Index (comorbidities)
0 309 (15.4) 6649 (51.0) <0.001
1 47 (2.3) 360 (2.8)
$2 81 (9.0) 1434 (11.0)
Not known 1465 (73.2) 4592 (35.2)
Diagnosis date (in relation to Cancer Plan)
Pre 2000 1336 (66.7) 8345 (64.0) 0.025
2000e2003 522 (26.1) 3667 (28.1)
Post 2003 144 (7.2) 1023 (7.8)
Presentation
Screening 61 (3.0) 2236 (17.2) <0.001
Symptoms 1527 (76.3) 8767 (67.3)
Incidental 117 (5.8) 475 (3.6)
Not known 297 (14.8) 1557 (11.9)
Radiotherapy
No 1014 (50.6) 2835 (21.7) <0.001
Yes 339 (16.9) 6996 (53.7)
Not known 649 (32.4) 3204 (24.6)
Chemotherapy
No 1107 (55.3) 5895 (45.2) <0.001
Yes 311 (15.5) 4092 (31.3)
Not known 584 (29.2) 3048 (23.4)
Tamoxifen
No 260 (13.0) 2233 (17.1) <0.001
Yes 1315 (65.7) 7916 (60.7)
Not known 427 (21.3) 2886 (22.1)
Total cases 2002 13035
*p Value for comparison of proportions, excluding ‘not known’
category where present. For age, Charlson Index and Cancer Plan,
test is for trend; for all other factors, test is for heterogeneity.
yp Value when ‘not known’ category is included: <0.001.
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independent of patient comorbidities, although this
should be interpreted with some caution, as comorbidity
data were available only for the 60% of participants who
could be successfully linked to the HES dataset. Surgery
was strongly associated with a reduced risk of early death,
and older patients were less likely to receive surgery.
Great improvements in cancer services have been
made during the past decade. To investigate whether the
implementation of the Cancer Plan has had any
observable effect on survival, this research included
a categorical variable controlling for calendar period of
diagnosis in the multivariate analyses. This method was
similar to that used by Rachet et al
8 in their assessment of
the NHS Cancer Plan for England. In our study, women
given a diagnosis after 2003 had reduced odds of early
death compared with women given a diagnosis before
the Cancer Plan was published (OR 0.71, 95% CI 0.52 to
0.98). This suggests a survival beneﬁt resulting from
changes to cancer services after 2000.
While women of white ethnicity were at greater odds of
early death in univariate analyses, this association was no
longer signiﬁcant when the model was adjusted for the
other covariates. The white women were in general older
than the non-white women, and this may explain these
ﬁndings. However, in the adjusted analysis, white women
were more likely to be treated surgically than those
belonging to non-white ethnic groups. These results
should perhaps be treated with caution, given the large
proportion (26%) of cases for which ethnicity was not
known.
Radiotherapy and tamoxifen treatments were inde-
pendently associated with reduced likelihood of early
death, while chemotherapy was associated with increased
odds of dying within a year of diagnosis (OR 1.49, 95%
1.19 to 1.86). This relationship with chemotherapy is
likely to be a reﬂection of selection bias, whereby only
the most severe cases are given this form of treatment. A
similar bias, but in the opposite direction, may apply to
surgerydthat is, with very ill patients selectively not
being operated upon. However, the association between
surgery and death within 1 year remained apparent in
a model correcting for age and comorbidity. These
ﬁndings are consistent with those in a recent study by
Brewster et al
22 that found age, deprivation, emergency
admission, tumour stage, and grade and absence of
treatment were independent factors associated with
death within 30 days of diagnosis.
A recent report from the National Cancer Intelligence
Network based on data from 2007 conﬁrms that a high
proportion of older women in the UK do not receive
surgical treatment: 61% of women aged over 80 did not
Table 5 Crude and adjusted ORs and 95% CIs for surgical treatment
Factor Number of cases
Surgical cases,
number (%)
OR (95% CI)
Unadjusted Adjusted*
Age at diagnosis (years)
<50 3800 3587 (94.4) 1.00 (e) 1.00 (e)
50e59 3739 3557 (95.1) 1.16 (0.95 to 1.42) 0.99 (0.80 to 1.22)
60e69 3042 2823 (92.8) 0.77 (0.63 to 0.93) 0.73 (0.59 to 0.89)
70e79 2643 2117 (80.1) 0.24 (0.20 to 0.28) 0.27 (0.23 to 0.33)
$80 1813 951 (52.5) 0.07 (0.06 to 0.08) 0.09 (0.07 to 0.10)
Ethnicity
Non-white 2058 1820 (88.4) 1.00 (e) 1.00 (e)
White 9098 8109 (89.1) 1.07 (0.92 to 1.25) 1.39 (1.16 to 1.65)
Not known 3881 3106 (80.0) 0.52 (0.45 to 0.61) 0.93 (0.77 to 1.11)
Distant metastases at diagnosis
No 8289 7609 (91.8) 1.00 (e) 1.00 (e)
Yes 427 276 (64.6) 0.16 (0.13 to 0.20) 0.16 (0.12 to 0.20)
Not known 6321 5150 (81.5) 0.39 (0.36 to 0.43) 0.36 (0.31 to 0.40)
Charlson Index (comorbidities)
0 (minor) 6958 6649 (95.6) 1.00 (e) 1.00 (e)
1 (moderate) 407 360 (88.5) 0.36 (0.26 to 0.49) 0.70 (0.49 to 0.99)
2+ (severe) 1615 1434 (88.8) 0.37 (0.30 to 0.45) 0.50 (0.41 to 0.62)
Not known 6057 4592 (75.8) 0.15 (0.13 to 0.17) 0.20 (0.17 to 0.23)
Diagnosis date (in relation to Cancer Plan)
Pre 2000 9681 8345 (86.2) 1.00 (e) 1.00 (e)
2000e2003 4189 3667 (87.5) 1.12 (1.01 to 1.25) 1.11 (0.97 to 1.27)
Post 2003 1167 1023 (87.7) 1.14 (0.95 to 1.37) 0.75 (0.60 to 0.94)
Presentation
Screening 2297 2236 (97.3) 1.00 (e) 1.00 (e)
Symptoms 10294 8767 (85.2) 0.16 (0.12 to 0.20) 0.34 (0.26 to 0.45)
Incidental 592 475 (80.2) 0.11 (0.08 to 0.15) 0.28 (0.20 to 0.40)
Not known 1854 1557 (84.0) 0.14 (0.11 to 0.19) 0.39 (0.29 to 0.53)
*Adjusted for all other factorsdthat is, based on model that includes all factors.
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23 This group is likely to have a particularly
poor prognosis. Nearly 40% of women who died early in
our study were aged 80 years or over, and 66% (252/383)
of them had not had surgery.
In our study, age was strongly inversely associated with
the likelihood of receiving surgery. This reﬂects the well-
described pattern in other studies of older women being
less likely to receive treatment than younger women.
10 24
Women over 80 years old attending breast units in
Manchester in 2002, for example, were less likely to have
surgery than women aged 65e79 years even after
adjustment for poorer general health, including
comorbidities.
11
Patient comorbidity has been shown to be a potentially
important confounder in studies of treatment
received,
15 25 but our analyses suggest that older women
are less likely to receive surgery even after adjustment for
comorbidities. Comorbidity data were missing for
approximately 40% of participants. Patients with missing
comorbidity data were less likely to receive surgery,
although there was no association between these missing
data and early death after adjustment for other factors.
One potential limitation of this study is missing
information. Women with missing data on ethnicity,
presentation and distant metastases were more likely to
die within a year of their diagnosis and were less likely to
receive surgical treatment. They may represent women
who were seriously ill at diagnosis and who were not
scheduled for surgery. An analysis of the characteristics
of patients with several missing data elements suggests
that these women tend to be older, have more severe
disease (as determined by a proxy of tumour size), and
are more likely to die early. In addition, a failure to
record important details relating to their diagnosis and
treatment may be an indication that such patients are
receiving worse care. With respect to this study, if women
with missing information have worse disease and are
generally older, then the estimates of association
between these variables and early death will be biased
towards underestimates of the true effects.
Retrospective analyses rely on records in which some
information may be inaccurate. In this study a particular
effort was made to ensure that the surgical status of
women was recorded correctly, as this was considered an
important marker of the quality of treatment and was
expected to be strongly associated with outcome. Time
and resource constraints precluded this additional effort
being extended to other variables to verify database
entries. However, an earlier study looking at trends in the
treatment of breast cancer
26 concluded that the audit
database was a reasonably reliable source of such data.
The effects of deprivation on disease severity and
ultimately on mortality were not explored in this study.
Such analyses rely on potential patient identiﬁers, such
as postcode data, that were not available to us. Depriva-
tion has been linked to poorer patient outcomes for UK
patients with breast cancer in several studies,
22 27e29 and
stated aims of the Cancer Plan and the Cancer Reform
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30e32 are to tackle the inequalities in cancer
survival between different socioeconomic groups in
England.
We suspect a complex relationship between the
exposures studied here, some of which may be on the
same causal pathway for early death. For example, high
age and comorbidity may be rational and adequate
reasons for not offering surgery. While a number of
patient and treatment characteristics were strongly and
independently linked with early death, these associations
must be interpreted with caution and with a consider-
ation for unmeasured confounding factors. For instance,
the selection of a patient’s treatment will depend on
a number of factors, including some not measured here,
such as their own preferences or established practices
within the organisation in which they are treated.
33
Furthermore, their presentation to health services
depends, among other factors, on access to those
services and knowledge of cancer symptoms. Many of
these variables may be linked to both risk factors and
outcomes and they have not been assessed in this study.
However, for any underlying confounder to explain the
strong statistical associations seen in our data, they
would need to have a very strong correlation with death
within a year of diagnosis.
Five-year relative survival in our sample (based on life
tables for London during the period 1996e2001) was
84.1%. This is similar to recent estimates from the Ofﬁce
for National Statistics,
34 which reports a value of 82% for
women given a diagnosis between 2000 and 2006. Thus
our cohort sample is likely to be reasonably representa-
tive of the UK population of women diagnosed as having
breast cancer during this period. Table 6 compares the
audit data with the total registrations for female breast
cancer in the North Thames region at TCR. Mean age at
diagnosis was similar throughout the study period.
Likewise, the proportion of patients dying within 1 year
of diagnosis was broadly similar, although slightly lower
in the audit database (6.5% vs 7.7% overall.) The
proportion of total cases represented in the audit varied
between 61% in 1997 and 13% in 2004, with an overall
ﬁgure of 37%. (The decrease in the number of regis-
tered cases in 2005 is an artefact due to changes in the
TCR catchment area.) In general, there was a higher
representation in the earlier years, which may have
implications for the applicability of the results to more
recent times.
CONCLUSIONS
Our ﬁndings offer detailed insights into the determinants
of death in the ﬁrst year after a diagnosis of breast cancer,
a period shown to be important in international compar-
isons. As expected, early death is linked to older age and
to the presence of comorbidities. Comorbidities can be
addressed in the long run through general health policy,
but two other determinants of early death identiﬁed by
this study are potential avenues for intervention.
First, the ﬁndings relating to disease severity lend
empirical support to the notion that late diagnosis is
a major determinant of early death. This supports the
rationale for projects that focus on increasing awareness
of breast symptoms and the importance of screening.
Second, surgery is independently associated with a large
reduction in the risk of early death, and older women
weredindependently of disease severity and comorbidi-
tydmuch less likely to receive surgery. Assuming surgery
is an indicator of attempts at curative treatment, there
may be beneﬁts of increased treatment activity for older
women.
Acknowledgements Ceilidh Stapelkamp undertook this work in a personal
capacity while completing her Master’s degree at King’s College London
Medical School, Department of Public Health and Division of Cancer Studies.
Funding This research received no speciﬁc grant from any funding agency in
the public, commercial or not-for-proﬁt sectors.
Competing interests None.
Contributors DR, LH and CS designed the study. DR, DT and CS collated and
analysed the data. CS wrote the ﬁrst draft, and DR, HM and LH ﬁnalised the
manuscript. All authors contributed to the interpretation of the data, and
reviewed and revised the manuscript, and have read and approved the ﬁnal
draft. All authors had full access to all of the data (including statistical reports
and tables) in the study and can take responsibility for the integrity of the data
and the accuracy of the data analysis.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data available.
REFERENCES
1. Berrino F, Verdecchia A, Lutz JM, et al. Comparative cancer survival
information in Europe. Eur J Cancer 2009;45:901e8.
2. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in
Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet
Oncol 2007;8:784e96.
3. Sant M, Capocaccia R, Verdecchia A, et al. Survival of women with
breast cancer in Europe: variation with age, year of diagnosis and
country. The EUROCARE Working Group. Int J Cancer
1998;77:679e83.
4. Møller H, Sandin F, Bray F, et al. Breast cancer survival in England,
Norway and Sweden: a population-based comparison. Int J Cancer
2010;127:2630e8.
5. Beral V, Peto R. UK cancer survival statistics. BMJ 2010;341:c4112.
6. Møller H, Richards S, Hanchett N, et al. Completeness of
case ascertainment and survival time error in English cancer registries:
impact on one-year survival estimates. Br J Cancer 2011;105:170e6.
7. Robinson D, Sankila R, Hakulinen T, et al. Interpreting international
comparisons of cancer survival: the effects of incomplete registration
and the presence of death certiﬁcate only cases on survival
estimates. Eur J Cancer 2007;43:909e13.
8. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival
trends in England and Wales up to 2007: an assessment of the NHS
cancer plan for England. Lancet Oncol 2009;10:351e69.
9. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373e83.
10. Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in
older surgical cancer patients: inﬂuence on patient care and outcome.
Eur J Cancer 2007;43:2179e93.
11. Lavelle K, Moran A, Howell A, et al. Older women with operable breast
cancer are less likely to have surgery. Br J Surg 2007;94:1209e15.
12. Haggstrom DA, Quale C, Smith-Bindman R. Differences in the quality
of breast cancer care among vulnerable populations. Cancer
2005;104:2347e58.
13. Ugnat AM, Xie L, Morriss J, et al. Survival of women with breast
cancer in Ottawa, Canada: variation with age, stage, histology, grade
and treatment. Br J Cancer 2004;90:1138e43.
14. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly
decreases prognosis of breast cancer in elderly women. J Clin Oncol
2003;21:3580e7.
15. Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in
postmenopausal breast cancer patients aged 55 years and older.
JAMA 2001;285:885e92.
Stapelkamp C, Holmberg L, Tataru D, et al. BMJ Open 2011;1:e000247. doi:10.1136/bmjopen-2011-000247 9
Predictors of early death in UK female breast cancer patients16. Busch E, Kemeny M, Fremgen A, et al. Patterns of breast cancer care
in the elderly. Cancer 1996;78:101e11.
17. Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors
associated with surgical and radiation therapy for early
stage breast cancer in older women. J Natl Cancer Inst
1996;88:716e26.
18. Eaker S, Dickman PW, Bergkvist L, et al. Differences in
management of older women inﬂuence breast cancer survival:
results from a population-based database in Sweden. PLoS Med
2006;3:e25.
19. Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key
explanation of differences in breast cancer survival across Europe. Int
J Cancer 2003;106:416e22.
20. Soerjomataram I, Louwman MW, Ribot JG, et al. An overview of
prognostic factors for long-term survivors of breast cancer. Breast
Cancer Res Treat 2008;107:309e30.
21. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node
status, and survival in 24,740 breast cancer cases. Cancer
1989;63:181e7.
22. Brewster DH, Clark DI, Stockton DL, et al. Characteristics of patients
dying within 30 days of diagnosis of breast or colorectal cancer in
Scotland, 2003-2007. Br J Cancer 2011;104:60e7.
23. National Cancer Intelligence Network. The Second All Breast Cancer
Report. NCIN, 2011. http://www.ncin.org.uk/home.aspx (accessed 19
Jun 2011).
24. Lavelle K, Todd C, Moran A, et al. Non-standard management of
breast cancer increases with age in the UK: a population based
cohort of women 65 years. Br J Cancer 2007;96:1197e203.
25. Cronin-Fenton DP, Norgaard M, Jacobsen J, et al. Comorbidity and
survival of Danish breast cancer patients from 1995 to 2005. Br J
Cancer 2007;96:1462e8.
26. Tataru D, Robinson D, Moller H, et al. Trends in the treatment of
breast cancer in Southeast England following the introduction of
national guidelines. J Public Health (Oxf) 2006;28:215e17.
27. Macleod U, Ross S, Gillis C, et al. Socio-economic deprivation and
stage of disease at presentation in women with breast cancer. Ann
Oncol 2000;11:105e7.
28. Macleod U, Ross S, Twelves C, et al. Primary and secondary care
management of women with early breast cancer from afﬂuent and
deprived areas: retrospective review of hospital and general practice
records. BMJ 2000;320:1442e5.
29. Downing A, Prakash K, Gilthorpe MS, et al. Socioeconomic
background in relation to stage at diagnosis, treatment and survival in
women with breast cancer. Br J Cancer 2007;96:836e40.
30. Department of Health. The NHS Cancer Plan: A Plan for Investment,
a Plan for Reform. London: Department of Health, 2000.
31. House of Commons. The NHS Cancer Plan: A Progress Report.
London: The Stationery Ofﬁce, 2005.
32. Department of Health. Cancer Reform Strategy. London: Department
of Health, 2007.
33. Hoy AR, Patrick H, Campbell B, et al. Measuring the inﬂuence of
colleagues on a consultant team’s use of breast conserving surgery.
Int J Technol Assess Health Care 2010;26:156e62.
34. Ofﬁce for National Statistics. Breast Cancer: Incidence Rates Rise,
Mortality Rates Fall. 2010. http://www.statistics.gov.uk/cci/nugget.
asp?id¼575 (accessed 19 Jun 2011).
PAGE fraction trail=9.5
10 Stapelkamp C, Holmberg L, Tataru D, et al. BMJ Open 2011;1:e000247. doi:10.1136/bmjopen-2011-000247
Predictors of early death in UK female breast cancer patients